The US Food and Drug Administration (FDA) recently approved a medical device that could bring new hope to patients suffering from rheumatoid arthritis (RA), a chronic autoimmune condition often ...

SetPoint Medical today announced the first patients in Chicago have been treated with the SetPoint System, an FDA-approved neuroimmune modulation therapy for adults living with moderately-to-severely ...

Credit: SetPoint Medical. The SetPoint System is a rechargeable neurostimulation device that is implanted on the vagus nerve. Treatment with the SetPoint System, a neuroimmune modulation device, was ...

An innovative new device calms inflammation by delivering a low-voltage jolt of electricity to the vagus nerve. The FDA has approved the SetPoint System, a device implanted in the neck for relieving ...

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today announced late-breaking data from the ...

SetPoint Medical has raised $140 million. This includes $25 million in the second tranche of its Series C financing, as well as $115 million in its Series D financing, co-led by Elevage Medical ...

VALENCIA, Calif., February 03, 2026--(BUSINESS WIRE)--SetPoint Medical today announced the first patients in Chicago have been treated with the SetPoint System, an FDA-approved neuroimmune modulation ...

Procedures performed by Dr. Webster Crowley mark a milestone for neuroimmune modulation therapy in the Midwest SetPoint Medical today announced the first patients in Chicago have been treated with the ...